Condition
Transthyretin Amyloid Cardiomyopathy clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Transthyretin Amyloid Cardiomyopathy clinical trials that are recruiting, at sites in 11 countries (most in Germany (2), Netherlands (1), Portugal (1)). By phase: Phase 1 (1), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 11Countries
Newest Transthyretin Amyloid Cardiomyopathy clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ocular Imaging to help detect ATTR-CM in adults with heart failure | — | Palo Alto, California and 19 other locations | Recruiting | Jul 8, 2026 |
| Coramitug PET/CT imaging to track and affect heart amyloid in ATTR-CM | Phase 1 | Groningen | Recruiting | Mar 4, 2026 |
| Switching from tafamidis to acoramidis to see how transthyretin blood levels change | Phase 4 | Sankt Pölten, Lower Austria and 25 other locations | Recruiting | Dec 22, 2025 |
| Characterizing wild-type transthyretin amyloidosis cardiomyopathy and its impact on quality of life | — | Aarhus, Arrhus N | Recruiting | Mar 4, 2024 |
All recruiting trials (4)
-
Ocular Imaging to help detect ATTR-CM in adults with heart failure
This multicenter pilot study tests whether eye imaging can help distinguish people with transthyretin amyloid cardiomyopathy from other heart failure patients.
-
Coramitug PET/CT imaging to track and affect heart amyloid in ATTR-CM
This study tests whether a radioactive version of the antibody coramitug can be detected in and displaced from heart amyloid in people aged 60 and older with transthyretin amyloid cardiomyopathy, and whether the drug is safe and well tolerated.
-
Switching from tafamidis to acoramidis to see how transthyretin blood levels change
This test will see if switching people with transthyretin amyloid cardiomyopathy who are taking tafamidis to acoramidis raises transthyretin levels in the blood.
-
Characterizing wild-type transthyretin amyloidosis cardiomyopathy and its impact on quality of life
This study is trying to understand how wild-type transthyretin amyloidosis cardiomyopathy affects the quality of life for patients at different stages of the disease compared to healthy individuals.
Related topics
Quick answers
How many Transthyretin Amyloid Cardiomyopathy clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 11 countries. The most sites are in Germany (2 trials), Netherlands (1 trial), Portugal (1 trial), Spain (1 trial), Sweden (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.